Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma

Fig. 4

OS prognostic performance of WEE2-AS1 in clinicopathological subgroups

(A) Forest plot of hazard ratios for the relationship between WEE2-AS1 and overal survival in TCGA cohort. (B)–(E) Kaplan–Meier plots of OS between expression of WEE2-AS1 and subgroups of patients with glioma in TCGA cohort. A high level of WEE2-AS1 is associated with poor survival outcomes in the age (B) and (C), G3 (D), and astrocytoma (E) subgroups

Back to article page